This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novavax (NVAX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $7.15, marking a +1.56% move from the previous day.
Amgen (AMGN) Q1 Earnings Beat Estimates
by Zacks Equity Research
Amgen (AMGN) delivered earnings and revenue surprises of 3.65% and 0.66%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Novavax (NVAX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed the most recent trading day at $7.53, moving -1.31% from the previous trading session.
Novavax (NVAX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Novavax (NVAX) is expected to provide updates on its ongoing clinical development in the first quarter of 2023.
Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $6.59, marking a -1.05% move from the previous day.
Novavax (NVAX) Down 2.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $5.76, marking a -0.35% move from the previous day.
Novavax (NVAX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed at $5.97 in the latest trading session, marking a +1.19% move from the prior day.
Novavax (NVAX) Q4 Earnings & Revenues Miss Estimates, Stock Down
by Zacks Equity Research
Novavax (NVAX) reports worse-than-expected financial performance in the fourth quarter of 2022, with earnings and revenues both missing the Zacks Consensus Estimate. Stock plunges 26.1% in response to the news.
Novavax (NVAX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Novavax (NVAX) delivered earnings and revenue surprises of -147.83% and 5.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug, Biotech Stocks' Q4 Earnings on Feb 28: NVAX, IOVA & More
by Kinjel Shah
Let us look at four drug and biotech companies, NVAX, IOVA, ALLO, SRPT and FATE, which are gearing up for their earnings release.
Bluebird Bio (BLUE) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Bluebird (BLUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed at $9.07 in the latest trading session, marking a -0.33% move from the prior day.
Novavax (NVAX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed the most recent trading day at $9.99, moving -1.96% from the previous trading session.
Novavax (NVAX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $9.88, marking a +1.02% move from the previous day.
Novavax (NVAX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Novavax's (NVAX) fourth-quarter earnings call, investors' focus is likely to be on the sales figures of its COVID-19 vaccine.
Omega Therapeutics, Inc. (OMGA) Surges 37.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Omega Therapeutics, Inc. (OMGA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Novavax (NVAX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed the most recent trading day at $11.09, moving -1.25% from the previous trading session.
The Zacks Analyst Blog Highlights Pfizer/BioNTech, Moderna and Novavax
by Zacks Equity Research
Pfizer/BioNTech, Moderna and Novavax are included in this Analyst Blog.
Novavax (NVAX) COVID Jab Aids Growth, Overdependence a Challenge (revised)
by Zacks Equity Research
Despite being one of the few authorized COVID-19 vaccine makers in the United States, Novavax's (NVAX) vaccine struggles for market share.
FDA Panel Endorses Simplification of COVID-19 Vaccine Strategy
by Zacks Equity Research
An FDA advisory committee unanimously votes in favor of using the same COVID-19 vaccine strain composition for primary series and booster doses.
Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed at $10.98 in the latest trading session, marking a -1.17% move from the prior day.
Novavax (NVAX) COVID Jab Aids Growth, Overdependence A Woe
by Zacks Equity Research
Despite being one of the few authorized COVID-19 vaccine makers in the United States, Novavax's (NVAX) vaccine struggles for market share.
Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $11.55, marking a -0.6% move from the previous day.
Novavax (NVAX) Gets Nod for COVID-19 Booster Jab in South Korea
by Zacks Equity Research
Novavax's (NVAX) COVID-19 vaccine gets approval in South Korea as a booster dose in adults 18 years and older.